Clinical Trials Browser

INDUSTRY × tucotuzumab celmoleukin × Clear all

NCT00408967 2017-08-18

Determine if Either of 2 Doses of Study Drug Given With a Low-dose of Cyclophosphamide After a Complete or Partial Response to a Platinum-based Second-line Therapy in Women With Recurrent Ovarian Carcinoma Results in a Longer Time to Progression When Compared to the First Time to Progression.

Phase 2 Withdrawn

Neoplasms, Ovarian Neoplasms, Recurrence

NCT00132522 2013-10-25

EMD 273066 in Patients With Recurrent EpCAM Positive Ovarian, Prostate, Colorectal or Non-small Cell Lung Cancers When First Given Cyclophosphamide

Phase 1 Completed

GastrointestinalGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

NCT00016237 2013-10-23

Interleukin-2 Combined With Monoclonal Antibody Therapy in Treating Patients With Kidney, Bladder, or Lung Cancer That Has Not Responded to Previous Treatment

Phase 1 Completed

GenitourinaryThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Kidney Neoplasms, Lung Neoplasms, Small Cell Lung Carcinoma